Andere talen Inozyme Pharma, Inc.

Aandelen

INZY

US45790W1080

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,44 ^USD	+2,54%		-1,55%	+4,23%

08/04	Transcript : Inozyme Pharma, Inc. - Special Call
08/04	Inozyme Pharma, Inc. Kondigt positieve topline-gegevens aan van lopende Fase 1/2-studies met INZ-701 bij volwassenen met Abcc6-deficiëntie (PXE) en ENPP1-deficiëntie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency	08/04
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	08/04
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/04
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024	26/03
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	26/03
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights	12/03
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference	26/02
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/02
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12
Inozyme Pharma to Participate in Upcoming Investor Conferences	09/11
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights	07/11
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/11
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023	26-10-23
Inozyme Pharma : ASBMR 2023 - ENPP1 Def. Interim Data	16-10-23
Inozyme Pharma : ASBMR 2023 - ABCC6 Def. Interim Data	16-10-23
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions	10-10-23
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions	10-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Inozyme Pharma, Inc.

Aandelen

INZY

US45790W1080

Andere talen

Filters